Aardvark Therapeutics Investors Face October 13 Class Action Deadline

The lawsuit, spearheaded by the Rosen Law Firm, centers on allegations that Aardvark Therapeutics provided investors with materially false information in its February 2025 IPO registration statement. Plaintiffs claim the company failed to disclose critical adverse facts, specifically that the drug ARD-101 possessed a less favorable safety profile than publicly represented. This alleged omission resulted in overstated clinical and regulatory prospects, ultimately causing financial harm to shareholders when the true details emerged.

Investors eligible to join the action include those who purchased common stock traceable to the company’s February 2025 IPO or acquired securities throughout the class period ending May 14, 2026. While the court has not yet certified a class, those seeking to represent the group as lead plaintiff must submit their motions by the October 13 deadline. Participation in the litigation carries no out-of-pocket costs for investors, as the firm operates on a contingency fee basis.